Compare Stocks: PEPG, OVID, and ERAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$15.32 -2.9%	$14.97	$2.50 ▼ $24.28	$5.32B	0.68	5.80 million shs	3.36 million shs
OVID Ovid Therapeutics	$2.41 -5.3%	$2.51	$1.18 ▼ $3.11	$453.90M	0.24	2.31 million shs	1.46 million shs
PEPG PepGen	$4.46 -11.6%	$2.77	$1.31 ▼ $7.80	$307.86M	2.02	1.64 million shs	2.41 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-6.07%	+18.91%	+6.77%	-14.15%	+495.47%
OVID Ovid Therapeutics	-8.27%	-1.16%	+16.44%	-9.89%	+93.18%
PEPG PepGen	-4.18%	+117.24%	+101.60%	+68.56%	-1.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$15.32 -2.9%	$14.97	$2.50 ▼ $24.28	$5.32B	0.68	5.80 million shs	3.36 million shs
OVID Ovid Therapeutics	$2.41 -5.3%	$2.51	$1.18 ▼ $3.11	$453.90M	0.24	2.31 million shs	1.46 million shs
PEPG PepGen	$4.46 -11.6%	$2.77	$1.31 ▼ $7.80	$307.86M	2.02	1.64 million shs	2.41 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-6.07%	+18.91%	+6.77%	-14.15%	+495.47%
OVID Ovid Therapeutics	-8.27%	-1.16%	+16.44%	-9.89%	+93.18%
PEPG PepGen	-4.18%	+117.24%	+101.60%	+68.56%	-1.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	2.64	Moderate Buy	$22.09	49.46% Upside
OVID Ovid Therapeutics	2.92	Moderate Buy	$6.00	149.48% Upside
PEPG PepGen	2.57	Moderate Buy	$11.40	153.05% Upside

Current Analyst Ratings Breakdown

Latest PEPG, OVID, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/13/2026	PEPG PepGen	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$7.00 ➝ $15.00
11/11/2026	PEPG PepGen	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$4.00 ➝ $10.00
11/10/2026	PEPG PepGen	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Underperform ➝ Neutral	$2.50 ➝ $6.00
10/15/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	OVID Ovid Therapeutics	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$5.00
10/15/2026	OVID Ovid Therapeutics	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$5.00
10/9/2026	OVID Ovid Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight
10/6/2026	OVID Ovid Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$7.00
10/5/2026	OVID Ovid Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$7.00
9/22/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/11/2026	OVID Ovid Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
OVID Ovid Therapeutics	$7.25M	62.61	N/A	N/A	$1.05 per share	2.29
PEPG PepGen	N/A	N/A	N/A	N/A	$1.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	N/A
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	N/A	-23.38%	-20.76%	N/A
PEPG PepGen	-$89.65M	-$1.07	N/A	N/A	N/A	N/A	-58.18%	-48.92%	N/A

Latest PEPG, OVID, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ERAS Erasca	-$0.1301	-$0.15	-$0.0199	-$0.15	N/A	$1.45 million
11/10/2026	Q3 2026	OVID Ovid Therapeutics	-$0.0848	-$0.10	-$0.0153	-$0.10	$0.03 million	N/A
11/10/2026	Q3 2026	PEPG PepGen	-$0.2707	-$0.28	-$0.0093	-$0.28	N/A	N/A
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	8.29	8.29
OVID Ovid Therapeutics	0.05	11.97	12.39
PEPG PepGen	N/A	8.70	13.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
OVID Ovid Therapeutics	72.24%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.20%
OVID Ovid Therapeutics	7.00%
PEPG PepGen	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
OVID Ovid Therapeutics	23	188.73 million	181.63 million	Optionable
PEPG PepGen	53	69.26 million	68.36 million	Optionable

PEPG, OVID, and ERAS Headlines

Recent News About These Companies

PepGen (NASDAQ:PEPG) Given New $15.00 Price Target at Guggenheim

2 hours ago | marketbeat.com

PepGen (PEPG) Stock Sees Fair Value Lift After Encouraging EDODM1 Analyst Reactions

November 12 at 11:59 PM | finance.yahoo.com

PepGen: Upgrade To 'Buy' On PGN-EDODM1 Splicing Data Comeback And 2027 Milestones

November 12 at 6:57 PM | seekingalpha.com

PepGen prices $125 million public offering at $5 per share

November 12 at 8:57 AM | streetinsider.com

PepGen Prices $125 Mln Offering Of 25 Mln Shares At $5.00 Per Share; Stock Up

November 12 at 8:57 AM | rttnews.com

PepGen: Positive Phase 2 Data Support Higher-Dose Study As Cash Reaches $104.8 Million

November 12 at 8:57 AM | pulse2.comP

PepGen (NASDAQ:PEPG) Stock Crosses Above Two Hundred Day Moving Average After Earnings Miss

November 12 at 2:11 AM | americanbankingnews.com

PepGen Announces Pricing of $125 Million Public Offering

November 11 at 10:22 PM | businesswire.com

PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes

November 11 at 5:00 PM | seekingalpha.com

PepGen’s stock skyrockets on record-breaking DM1 trial data

November 11 at 2:36 PM | finance.yahoo.com

Traders Buy Large Volume of PepGen Call Options (NASDAQ:PEPG)

November 11 at 11:19 AM | marketbeat.com

PepGen’s Myotonic Dystrophy Drug Sets Phase 2 Efficacy Record: FDA Hold Still Bars American Patients

November 11 at 9:35 AM | techtimes.comT

PepGen (NASDAQ:PEPG) Stock Price Target Raised at Wedbush

November 11 at 9:11 AM | marketbeat.com

PepGen Stock Soars 129% Despite Wider Q3 Loss

November 11 at 4:34 AM | rttnews.com

PepGen stock soars over 100% on positive Phase 2 trial data for DM1 drug

November 11 at 4:34 AM | finance.yahoo.com

Stock Traders Purchase Large Volume of Put Options on PepGen (NASDAQ:PEPG)

November 11 at 4:31 AM | americanbankingnews.com

PepGen (NASDAQ:PEPG) Shares Cross Above 200-Day Moving Average on Disappointing Earnings

November 10 at 12:19 AM | marketbeat.com

PepGen launches $125M public stock offering

November 10 at 11:34 PM | streetinsider.com

PepGen launches $125M public stock offering

November 10 at 11:34 PM | streetinsider.com

PepGen reports phase 2 myotonic dystrophy trial results and $104.8 million cash position

November 10 at 11:34 PM | msn.com

PepGen reports phase 2 myotonic dystrophy trial results and $104.8 million cash position

November 10 at 11:34 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PEPG, OVID, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

$15.32 -0.46 (-2.91%)

As of 11:57 AM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Ovid Therapeutics NASDAQ:OVID

$2.41 -0.14 (-5.33%)

As of 11:56 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

PepGen NASDAQ:PEPG

$4.46 -0.59 (-11.61%)

As of 11:57 AM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, OVID, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, OVID, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, OVID, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEPG, OVID, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

Ovid Therapeutics NASDAQ:OVID

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, OVID, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, OVID, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, OVID, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEPG, OVID, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

Ovid Therapeutics NASDAQ:OVID

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools